Fate Therapeutics
FATE
103 hedge funds and large institutions have $488M invested in Fate Therapeutics in 2018 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 39 increasing their positions, 21 reducing their positions, and 16 closing their positions.
116% more capital inflows, than outflows
Capital inflows: $75.6M | Capital outflows: $35M
86% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 21
81% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 16
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
46% more call options, than puts
Call options by funds: $2.34M | Put options by funds: $1.6M
14% more funds holding
Funds holding: 90 → 103 (+13)
6.73% more ownership
Funds ownership: 74.69% → 81.42% (+6.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$13.3M |
| 2 |
AG
Artal Group
Luxembourg
|
+$9.36M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
+$8.87M |
| 4 |
Millennium Management
New York
|
+$7.55M |
| 5 |
BlackRock
New York
|
+$4.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$14.2M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$3.5M |
| 3 |
6CM
683 Capital Management
New York
|
-$2.75M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$2.4M |
| 5 |
Bridgeway Capital Management
Houston,
Texas
|
-$1.97M |
FATE Hedge Fund Activity: Q2 2018 in Review
103 of the 4,386 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q2 2018, worth a combined $488M — up 27% from $385M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new FATE positions and 16 closed out — a net gain of 13 holders — while 39 added to existing stakes and 21 trimmed.
The largest buyer was State Street, adding an estimated $13.3M. The largest seller was Fidelity Investments, cutting an estimated $14.2M.
- 103 institutional investors held Fate Therapeutics (FATE) as of Q2 2018, up from 90 in Q1 2018.
- Funds reported $488M of Fate Therapeutics stock for Q2 2018, up 27% quarter-over-quarter.
- 29 funds opened new Fate Therapeutics positions in Q2 2018 and 16 closed out, a net change of +13 holders.
- The largest Fate Therapeutics buyer in Q2 2018 was State Street, an estimated $13.3M added.
- The largest Fate Therapeutics seller in Q2 2018 was Fidelity Investments, an estimated $14.2M sold.
Based on aggregated 13F filings for Q2 2018.